linjc16/ctgov huggingface dataset:
The Influence of the Thickening of Bowman's Capsule on the Clinical Prognosis of Patients With Diabetic Kidney Disease

Study Overview
=================
Brief Summary
-----------------
Diabetic kidney disease (DKD) is the leading cause for renal replacement therapy in developed country. DKD is also the primary cause of ESKD among middle-aged and elderly people in China. Renal pathological markers have been proved to have clinical and prognostic value in both non diabetic and diabetic kidney diseases. To discriminate lesions by various degrees of severity, the Working Group of the Renal Pathology Society (RPS) developed a pathologic classification for DKD in 2010. The classification is based on glomerular lesions, with a separate evaluation for interstitial and vascular lesions. In a decade, there were several new characteristics common to DKD, such as the presence of mesangiolysis, glomerular hyalinosis, segmental sclerosis and extracapillary hypercellularity, which have been noted in patients with diabetes and may have prognostic importance. But it is still unclear whether thickening of Bowman's capsule predicts the progression of DKD.

Official Title
-----------------
The Influence of the Thickening of Bowman's Capsule on the Clinical Prognosis of Patients With Diabetic Kidney Disease

Conditions
-----------------
Diabetic Kidney Disease, Extracellular Matrix Alteration

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1) Age ≥ 18 years old, male or female 2) Patients diagnosed as diabetes kidney disease by renal biopsy Exclusion Criteria: 1) Patients combined with non diabetes kidney disease; 2) Patients with kidney transplant failure; 3) Patients undergoing zero point puncture for kidney transplantation; 4) less than 5 glomeruli in the renal puncture sample.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| mild thicknening of Bowman's Capsule<br> | Other: no intervention<br>* no intervention<br>|
| severe thickening of Bowman's Capsule<br> | Other: no intervention<br>* no intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| renal failure | estimated glomerular filtration rate（eGFR）<15ml/min/1.73m2, renal replacement treatment or death caused by renal disease | From the diagnosis of diabetes kidney disease by renal biopsy to December 31, 2022 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetic Kidney Disease, extracellular matrix, parietal epithelial cells
The Study of Sleep Disordered Breathing in Patients With Interstitial Lung Diseases

Study Overview
=================
Brief Summary
-----------------
This was a cross-sectional observational study to evaluate the prevalence and predictive factors of SDB in ILD and to analyze the relationship between polysomnography (PSG) findings, pulmonary function, disease severity, parenchymal involvement, and sleep questionnaires ESS and SBQ. This study included 69 patients who were diagnosed with diffuse parenchymal lung diseases by high-resolution computed tomography (HRCT) chest. All patients were subjected to clinical examination, HRCT, spirometry, full-night polysomnography, and echocardiography.

Official Title
-----------------
Study of the Prevalence and Predictive Factors of Sleep Disordered Breathing in Patients With Interstitial Lung Diseases

Conditions
-----------------
Obstructive Sleep Apnea-hypopnea

Intervention / Treatment
-----------------
* Diagnostic Test: Polysomnography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Both sexes of clinically stable ILD patients older than 18 who met the ATS/ERS criteria for an ILD diagnosis were included in the study. Exclusion Criteria: Patients who have any anatomic upper airway obstructions such as significant nasal septal deviation, nasal polyps, conchae hypertrophy or tonsillar hypertrophy. Patients with neurological diseases or severe psychiatric disorders. Patients who have history of administration of any drug that has a major effect on sleep e.g. benzodiazepine, narcotic drugs ….etc. Patients with any chronic pulmonary disease except ILD. Total sleep time less than 4 hours on PSG.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| OSA group<br>The group of patients who had sleep disordered breathing | Diagnostic Test: Polysomnography<br>* Polysomnography is done for patients to find any sleep disordered breathing<br>* Other names: Sleep study;|
| No OSA group<br>The group of patients who had not sleep disordered breathing | Diagnostic Test: Polysomnography<br>* Polysomnography is done for patients to find any sleep disordered breathing<br>* Other names: Sleep study;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurements of apnea hypopnea index | Polysomnography can measure apnea hypopnea index of all patients to detect sleep disordered breathing | 1and half years |
Chronic Unilateral Lumbar Radicular Pain

Study Overview
=================
Brief Summary
-----------------
Chronic neuropathic lumbar pain is among one of the most widespread complaints of patients.Many approaches have been attempted to target chronic pain, with varying efficacy and risks. Transgrade (TG) epidural injection is a new technique using a Racz- Coudé needle for epidural access at a transgrade angle without requiring any specialized hardware or accessories. Interlaminar (IL) epidural steroid injection (ESI) is one of the procedures that involves the delivery of injectate to the epidural space through directing a needle between the laminae of two adjacent vertebrae.

Official Title
-----------------
Effectiveness of Transgrade vs Interlaminar Epidural Steroid Injection for Chronic Unilateral Lumbar Radicular Pain

Conditions
-----------------
Neuropathic Pain

Intervention / Treatment
-----------------
* Other: Transgrade technique (TG)
* Other: Interlaminar technique (IL)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: > 6-month history of persistent pain in one leg with back pain. Capable of giving informed consent. Unsatisfactory response to conventional treatments including physical therapy or medications with a numeric rating scale (NRS) ≥ 5. Exclusion Criteria: Previous lumbar spinal surgery. Myelopathy. Rheumatoid disorders. Psychiatric disorders Bleeding or coagulation disorders

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Transgrade technique (TG)<br> | Other: Transgrade technique (TG)<br>* Transgrade (TG) Epidural Steroid Injection technique<br>|
| Active Comparator: Interlaminar technique (IL)<br> | Other: Interlaminar technique (IL)<br>* Interlaminar (IL) Epidural Steroid Injection technique<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The average numeric rating scale (NRS) pain scores | The numeric rating scale (NRS) is most commonly 0 to 10, with 0 being no pain and 10 being the worst pain imaginable. | at 12 weeks after intervention |
Observational, Prospective, Cohort Study of Mpox Infection in Brazil (NETPOX)

Study Overview
=================
Brief Summary
-----------------
The study is a prospective cohort that evaluates the clinical and immune-metabolic variables that may be linked to the risk and severity of the infection or even hospitalization or death in patients infected with the Mpox virus in Brazil. The expectation is to include at least 80 patients over six months, with a follow-up of 90 days from inclusion, through contact via decentralized visits.

Official Title
-----------------
Observational, Prospective, Cohort Study of Mpox Infection in Brazil - NETPOX Cohort

Conditions
-----------------
Monkeypox, MPOX

Intervention / Treatment
-----------------
* Diagnostic Test: Viral genomic
* Diagnostic Test: Untargeted Metabolomics


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men and women aged ≥ 18 years with confirmed MPOX infection. (laboratory-confirmed monkeypox infection is defined as determined by PCR, culture, or antigen test obtained from a sample collected from blood, oropharynx, anal or skin lesion within 4 days of randomization) Exclusion Criteria: Inability to provide informed consent; Patient who, judging by the study team, does not have a condition for decentralized follow-up

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Human cases of monkeypox confirmed by PCR<br>Laboratory-confirmed mpox infection is defined as determined by polymerase chain reaction assay (PCR), culture, or antigen test obtained from a sample collected from blood, oropharynx, anal or skin lesion within 5 days of inclusion. | Diagnostic Test: Viral genomic<br>* Evaluation of mpox viral genomic<br>Diagnostic Test: Untargeted Metabolomics<br>* Evaluation of metabolomics of the total plasma, oropharynx, and skin samples.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composed of incidence of rash, fever, adenopathy, general pain, chills, weakness, occurrence of hospitalization, and neurological repercussions | symptoms' incidence in participants with mpox infection | Up to 90 days after the inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Death | Incidence of death | Up to 90 days after the inclusion | 
| Hospitalizations | Incidence of hospitalization | Days 15, 30, 60, and 90 | 
| Untargeted metabolomics of total plasmas and skin lesion | Changes among visits of Immune-metabolomics responses related to symptoms' incidence | Days 15, 30, 60, and 90 | 
| Viral genomic | Evaluation of the pattern of viral genome of the mpox virus circulation in Brazil | Day 0 |
Validation of a Simultaneous Ocular/Cervical VEMP With Mastoid Vibration by B250

Study Overview
=================
Brief Summary
-----------------
A Validation study in which the standard separate cVEMP and oVEMP will be compared with a new protocol in which the cVEMP and oVEMP can be recorded simultaneously in response to a mastoid vibration by bone transducer B250

Official Title
-----------------
Validation of a Simultaneous Ocular/Cervical VEMP With Mastoid Vibration by B250

Conditions
-----------------
Vertigo

Intervention / Treatment
-----------------
* Diagnostic Test: VEMP by bone conduction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -) dizzy patients attending the balance laboratory - Exclusion Criteria: -) age < 18 years old
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: VEMP by bone conduction|New bone conducted VEMP elicited by transducer B250|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| response rate |  | during the procedure |
Insights Into Participating in Clinical Studies for Anorexia

Study Overview
=================
Brief Summary
-----------------
Clinical trials centered on anorexia serve a pivotal function in assessing the safety and effectiveness of emerging treatments for this condition. The primary aim revolves around meticulously scrutinizing both trial completion rates and instances of voluntary withdrawal within specific patient cohort.

Official Title
-----------------
Assessing Engagement Patterns and Participation Trends in Individuals Joining Anorexia Clinical Trials

Conditions
-----------------
Anorexia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed Diagnosis of anorexia No prior treatment for anorexia Exclusion Criteria: Pregnant or lactating women Any serious and/or unstable pre-existing medical disorders Patients receiving any other investigational agents

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients who decide to enroll in an anorexia clinical research |  | 3 months | 
| Rate of patients who remain in an anorexia clinical trial to trial completion |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
anorexia
A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study

Study Overview
=================
Brief Summary
-----------------
Clinical studies, with a distinct emphasis on medullary thyroid cancer, play a pivotal role in evaluating the safety and effectiveness of novel treatments for this condition. These trials serve as essential tools to determine whether new medications surpass conventional therapies, providing substantial evidence to endorse their broader adoption. The primary objective is to meticulously examine trial completion rates and voluntary withdrawals within this specific patient group. By actively participating in this observational study plays a critical role in pushing medical knowledge forward and advancing care for individuals suffering from the medullary thyroid cancer.

Official Title
-----------------
Analyzing the Patterns of Patient Engagement and Trends in Participation Observed in Medullary Thyroid Cancer Clinical Trials

Conditions
-----------------
Medullary Thyroid Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed diagnosis of medullary thyroid cancer Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed No serious medical or psychiatric illness likely to interfere with participation in this clinical study. Exclusion Criteria: Is pregnant, breastfeeding or expecting to conceive within the projected duration of the study Any serious and/or unstable pre-existing medical disorders Patients who are currently receiving any other investigational drug.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of medullary thyroid cancer patients who decide to enroll in a clinical trial |  | 3 months | 
| Rate of medullary thyroid cancer patients who remain in clinical trial to trial completion |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Medullary Thyroid Cancer
Enteral Feeding of Premature Babies and Olive Oil Supplementation

Study Overview
=================
Brief Summary
-----------------
It is a two-arm prospective interventional study. 40 babies in both groups will be enrolment in the study. In the intervention group, babies will take 1 ml/kg/day of the study product (ULTRA PREMIUM) after full enteral feeding. Supplementation will continue until discharge or the 36th week. Blood samples will be taken for serum Total antioxidant capacity and Malondialdehyde levels before the intervention and on the 14th day of the control group. At the end of the study, serum will be taken again for control values. Daily lipid intake amounts will be recorded through breast milk analysis. Lipid profile will be monitored weekly The growth parameters of babies will be monitored daily It will be evaluated at the end of the study in terms of ROP, BPD, and NEC. At the end of the study, the data of babies in both groups will be compared.

Official Title
-----------------
The Effect of Enteral Organic Extra Virgin Olive Oil Supplementation in Premature Babies on Postnatal Growth and Premature Morbidities

Conditions
-----------------
Premature, Olive Oil, Enteral Feeding

Intervention / Treatment
-----------------
* Dietary Supplement: Extra virgin organic olive oil (ULTRA PREMIUM)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Premature babies born at 32 weeks or less Babies who tolerate full enteral feeding at the before end of the second week Babies given consent by their parents - Exclusion Criteria: Having a congenital or genetic anomaly

Ages Eligible for Study
-----------------
Minimum Age: 14 Days
Maximum Age: 40 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Olive oil group<br>Babies who have fully enteral feeding will take oral, 1 ml/kg/day of extra virgin olive-oil | Dietary Supplement: Extra virgin organic olive oil (ULTRA PREMIUM)<br>* Babies who have fully enteral feeding will take oral, 1 ml/kg/day of extra virgin olive-oil<br>|
| No Intervention: Control group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients who completed the study | To enrolment of 40 babies in the study in both groups | 15 months | 
| Postnatal growth retardation rates | Daily weight intake amounts of babies in both groups | 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency and severity of retinopathy of prematurity | Frequency and severity of retinopathy of prematurity | 18 months |
A Predictive Model for Early Metastasis in Cervical Cancer Patients After Radiotherapy

Study Overview
=================
Brief Summary
-----------------
This study aims to help to screen out appropriate cases for consolidation therapy and more intensive follow up.

Detailed Description
-----------------
Some cervical cancer patients experienced distant metastasis quickly after receiving complete radiotherapy and have a worse prognosis. However, there were few studies focused on these patients and with early distant metastasis. It is significant to predictive and screen out cervial cancer patients with a high risk of early metastasis for more comprehensive treatments and follow-up plans

Official Title
-----------------
A Novel Predictive Model and Risk Stratification for Early Metastasis in Cervical Cancer Patients After Radiotherapy

Conditions
-----------------
Cervical Cancer, Radiotherapy, Distant Metastasis, Prognostic Model, Risk Factor

Intervention / Treatment
-----------------
* Radiation: external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients confirmed as cervical cancer by biopsies and treated with radiotherapy were initially enrolled Exclusion Criteria: (1) patients treated with surgery. (2) patient received incomplete treatment somewhere else. (3) patients with cancer history. (4) patients with pelvic surgery history. (5) patients without complete pre-treatment medical information. (6) patients with unfinished radical radiotherapy. (7) patients suffered from metastasis within 3 months after radiotherapy. (8) patients without complete 1-year follow-up materials

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cervical cancer patients with radiotherapy<br>The overall dose should be more than 75 Gy. patients received surgery should be excluded. | Radiation: external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT)<br>* Radical RT consisted of external pelvic beam radiotherapy (EBRT) and individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT).Cisplatin-based concurrent chemoradiotherapy (CCRT) was recommended for CC patients unless for economic status, age consideration and patients' desires.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Early distant metastases | Early distant metastasis defines as metastasis occurrence between 3 -12 months after radiotherapy. | 3-12months |